Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
Summary
Jing Bao, Senior Advisor of Shanghai HealthCare Capital with a PhD from the Weizmann Institute of Science, commented: "Microbiome research is an attractive field for SHC. "Added Ofer Haviv, Chairman of Biomica and President & CEO of Evogene, "We are pleased to bring this new strategic partner, Shanghai Healthcare Capital, to join us. "Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Currently, Evogenes main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com.Shanghai Healthcare Capital was authorized by Shanghai Municipal Government and founded by Shanghai Industrial Investment (Holdings) Co., Ltd, with a total targeted asset under management of 50 billion RMB. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.